Abstract:Ruoxin Fang, &ast Sha Xu, &ast Jun Gong, Zhengkai Liao Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, Hubei, 430071, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhengkai Liao, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, People's Republic of China, Email Aim: BRAF is a pivotal driver gene in cancer development. Based on this, the combination of dabrafenib and trametinib was approved for treating NSCLC patients with BRAF V600E mutations. However, the majority of BRAF mutations in lung cancer are non-V600E variants, particularly class III mutants, which currently lack targeted therapeutic options and result in unfavorable clinical outcomes. Case Presentation: We present a case of advanced lung adenocarcinoma with a class III BRAF G466V mutation. The patient experienced significant pleural and pericardial effusion, leading to chest tightness and an inability to lie flat. Severe pain and limited mobility from lumbar destruction seriously affected the patient's quality of life. Due to the patient's intolerance to chemotherapy, dabrafenib and trametinib combination therapy was chosen. After three months of targeted therapy, the patient's overall condition significantly improved, enabling self-care, and achieving partial response (PR) as an indicator of treatment efficacy. Conclusion: The combination therapy of dabrafenib and trametinib demonstrates remarkable clinical benefits for lung adenocarcinoma patients with the BRAF G466V mutation. Targeted therapy should be considered for patients with BRAF class III mutations, especially those in poor general condition and may not tolerate chemotherapy. Keywords: case report, NSCLC, BRAF G466V, targeted therapy, dabrafenib, trametinib The emergence of targeted tyrosine kinase inhibitor (TKI) therapy has significantly improved survival outcomes and quality of life in advanced lung cancer patients, particularly those with lung adenocarcinoma. 1 Common driver genes in lung cancer include EGFR, ALK, ROS1, etc. The BRAF gene mutation is relatively rare, accounting for approximately 4.5% of all lung cancer cases, with over 50%, classified as non-V600E mutations. 2 The BRAF's basal kinase activity surpasses that of other RAF family members. 3 RAF kinases transmit signals from Ras to downstream dual-specificity protein kinases MEK1 and MEK2, which then phosphorylate and activate serine/threonine-specific protein kinases MAPK1/ERK1 and MAPK2/ERK2. 4 This pathway is closely related to cellular proliferation, differentiation, survival, cytoskeleton and other functions. 5 As a result, BRAF has become a crucial focus for oncology therapy. The BRAF V600E mutation is the most prevalent alteration in the BRAF gene. Currently, dabrafenib and trametinib are approved for treating non-small cell lung cancer (NSCLC) patients with BRAF V600E mutation. 6 However, effective targeted therapy for non-V600E mutations of BRAF is still under development. Studies in advanced melanoma with rare BRAF mutations have shown that BRAF inhibitors combined with MEK inhibitors (BRAF/MEK inhibitors) resulted in a median overall survival (OS) of 11.3 months, 7 suggesting potential efficiency for non-V600 mutations, but evidence in NSCLC is limited. The BRAF mutations can be categorized into three distinct groups: class I comprises autonomously activating BRAF V600 mutations in the RAS pathway. In contrast, class II and III include BRAF non-V600 mutations. Class III mutations hinder kinase activity, relying on RAS activation, and wild-type CRAF functions as an enhancer of the RAS signaling pathway. 8 Recent findings indicate that NSCLC patients with BRAF class III mutations have a poorer response to platinum-containing chemotherapies compared to those with BRAF V600E mutations. 9 The BRAF G466V mutation, is a class III alteration, potentially confers increased tumor aggressiveness 10 and lacks targeted therapeutic options. Here, we describe a novel case of advanced lung adenocarcinoma harboring the rare BRAF G466V mutation. This case exhibited a substantial positive reaction to initial targeted treatment with dabrafenib and trametinib. Our report adheres to the CARE checklist. 11 On April 11, 2023, a 68-year-old man with a history of heavy smoking and hypertension, visited Zhongnan Hospital of Wuhan University. He had worsening lower back pain for the past 2 m -Abstract Truncated-

Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E

BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report

A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: a case report and literature review

Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression

Molecular Mechanisms Underlying the Resistance of BRAF V600E-mutant Metastatic Colorectal Cancer to EGFR/BRAF Inhibitors

BRAF p.V600E Mutation as Acquired Resistance Mechanism of Lorlatinib in a ROS1 Rearrangement Lung Adenocarcinoma Patient with Primary Ceritinib Resistance

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report

MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

Efficacy of Vemurafenib in a Heavy Smoker with BRAF-mutated Lung Adenocarcinoma: A Case Report and Literature Review.

Osimertinib-induced BRAF mutation in a single metastatic lesion among multiple pulmonary lesions in a case of lung cancer with EGFR exon 19 deletion

EP1.14-46 the KIF5B-RET Fusion As a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report

Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors

Features and efficacy of triple-targeted therapy for patients with EGFR -mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors

Molecular characteristics and treatment strategy in advanced, EGFR-mutant non-small cell lung cancer with concomitant BRAF variations.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients